Small Cell Lung Cancer: Global Clinical Trial Landscape (2024)

Small cell lung cancer accounts for approximately 10-15% of all lung cancer cases globally. Globally, it continues to pose a significant health burden, with an estimated 400,000 new cases documented. However, treatment in the field is accelerating at pace. Since 2019, the biotech and biopharma industry initiated around 1,200 small-cell lung cancer trial studies with Asia-Pacific leading in the number of clinical trials conducted. Download the free report now to get the latest data-driven insights on current fields of research, with personalised approaches, immune checkpoint inhibitors, PARP inhibitors, and antibody-drug conjugates playing key roles in developments.